PBYI News and Press, Puma Biotechnology Inc From 11/23/21

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent No. 7,399,865, extending the patent term five (5) years. The patent includes composition ...

Puma Biotechnology (NASDAQ:PBYI) presents results from the neratinib arm of the Phase II INSIGhT Trial at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting. PBYI shares up 11.4% premarket at $3.81. The INSIGhT trial is a Phase II screening adaptive platform trial where patients with ne...

Puma Biotechnology (NASDAQ:PBYI) is extending the post-market losses with a ~26.0% decline in early hours after the company’s Q3 2021 financials lagged expectations. Total revenue fell short of Street forecasts by as much as $7.2M after recording a ~9.1% YoY decline to r...

Puma Biotechnology, Inc. (PBYI) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and Chief Executive Officer Jeffrey Ludwig - Chief Commercial Officer Maximo Nougues - ...

Gainers: Ontrak (NASDAQ:OTRK) +29%. BigCommerce Holdings (NASDAQ:BIGC) +17%. Farmer Brothers Company (NASDAQ:FARM) +17%. JFrog (NASDAQ:FROG) +13%. Expedia Group (NASDAQ:EXPE) +11%. Losers: Peloton Interactiv (NASDAQ:PTON) -26%. Applied Optoelectronics (NASDA...

Puma Biotechnology (NASDAQ:PBYI): Q3 Non-GAAP EPS of -$0.99 misses by $0.77; GAAP EPS of -$1.09 misses by $0.78. Revenue of $46.2M (-9.1% Y/Y) misses by $7.24M. Shares -6.1%. Press Release For further details see: Puma Biotechnology EPS misses by $0.77, misses on revenue

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2021. Unless otherwise stated, all comparisons are for the third quarter of 2021 compared to the third quarter of 2020. Product revenue, net co...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:00 a.m. EDT on Tuesday, September 28, at the 2021 Cantor Virtual Global H...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference, ...

Puma Biotechnology recently reported their Q2 earnings that revealed a beat on EPS and revenue. Unfortunately, the market continues to crush PBYI, which is down ~50% from February. The company reported respectable sequential growth and improvements in commercial trends. It appears the...